Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Section 5 of 6

Economic information and modeling report

37 evidence topics · 29 sources

Modeling overview

Summary: adrabetadex price and comparator prices

  • Adrabetadex: no list price for Lembaz had been announced at approval; trade press reporting states that “List pricing for the new product has not yet been announced”. No budget impact model or cost-effectiveness analysis of adrabetadex has been published.
  • ICER launch price report: the ICER Launch Price and Access Report (2026) gives an annual list price of $967,432.50 and a best annual net price estimate of $940,586.25 for Miplyffa (arimoclomol), using the dosing regimen for patients weighing 30 kg to 55 kg, and an annual list price of $701,321.42 and a best annual net price estimate of $576,661.54 for Aqneursa (levacetylleucine), using the dosing regimen for patients weighing 35 kg or more. ICER converted unit WAC prices to annual WAC prices using the dosage information on the FDA label, and had not previously reviewed the clinical effectiveness and cost-effectiveness of either drug.
  • Arimoclomol: the wholesale acquisition cost of Miplyffa at its introduction on September 23, 2024 was $40,185 (47 mg), $53,010 (62 mg), $79,515 (93 mg), and $106,020 (124 mg), and the same values were reported to Texas for 1 January 2026. Federal Supply Schedule prices effective 01/01/2026 for a package of 90 range from $30,080.19 (47 mg) to $79,360.50 (124 mg).
  • Levacetylleucine: the wholesale acquisition cost of an Aqneursa 1 gram sachet carton of 28 was $13,450 at its introduction on September 24, 2024 and on 1 January 2025, and the wholesale acquisition cost reported for Aqneursa on 1 January 2026 was $14,526. The Federal Supply Schedule price for a package of 28 is $13,339.54 and the Big Four price is $10,206.02. An Oklahoma Medicaid review gives $480.36 per packet, $57,643.20 per 30 days, and $691,718.40 per year at the FDA approved maximum dose of 4 g per day, based on NADAC, WAC, or SMAC and excluding rebates.
  • Miglustat: Zavesca 100 mg has a Federal Supply Schedule price of $16,811.69 and a Big Four price of $12,589.91 for a package of 90, and a generic miglustat 100 mg product has a Federal Supply Schedule price of $4,644.83.
  • Utilization and revenue: Zevra reported $34.0 million in Miplyffa revenue for the third quarter of 2026, 197 Miplyffa prescription enrollment forms since launch, and 134 participants enrolled in its global EAP as of September 30, 2026. Analysts at Delveinsight expect Aqneursa to generate $500 million in peak U.S. sales in NPC.

Summary: eligible population and market size

  • United States population: a database analysis identified 294 individuals with an NPC diagnosis among 308 million unique individuals, an identified prevalence of 0.95 per million, and estimated 943 prevalent cases of NPC, or 2.9 cases per million people in the United States. Beren Therapeutics states that approximately half of those living with NPC in the U.S., or 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the U.S. remain undiagnosed.
  • Developer estimates for comparators: the developer of arimoclomol estimates approximately 2,000 individuals with NPC in the United States and Europe combined, approximately 900 of them in the United States, of whom approximately 300 to 350 have been diagnosed, and states that nearly half of the people treated with Miplyffa are adults. In manufacturer filings with California at launch, the estimated number of patients was 300 for Miplyffa and 200 for Aqneursa. Over the year from 4/1/24 to 3/31/25, 8 Oregon Health Plan members had a diagnosis indicating NPC in their medical claims.
  • Market size: the developer of remibetadex expects the global market to reach more than $920 million by 2033 and presents an illustrative revenue matrix of per-patient annual price by patients treated as a percentage of approximately 943 prevalent cases, which it labels as illustrative and not a forecast.
  • Priority review vouchers: on April 1, 2025, the developer of arimoclomol completed the sale of the rare pediatric disease priority review voucher it received with an approval, for net proceeds of $148.3 million, and the developer of remibetadex states that the four most recent vouchers sold for an average of approximately $200 million and that the program was extended to September 2029.

Summary: health technology assessments and published economic analyses

  • Adrabetadex: the NICE appraisal of VTS-270 for Niemann-Pick type C1 was suspended after information the company provided in July 2023 and then discontinued, and the company advised that it is no longer pursuing a Marketing Authorisation Application from the MHRA for this indication.
  • Comparators outside the United States: the NICE appraisal of arimoclomol was suspended after a statement by Orphazyme on 23 February 2022. The Scottish Medicines Consortium does not recommend miglustat for Niemann-Pick type C disease because the marketing authorisation holder made no submission. Ontario's Ministry considers requests for reimbursement of Zavesca (miglustat) for NPC under stated criteria.
  • Oregon Medicaid: the Oregon State University Drug Use Research and Management Program reviewed Miplyffa and Aqneursa in December 2025 and found low-certainty evidence from one phase III crossover trial (n=60) that levacetylleucine improves ataxia symptoms over 12 weeks and no comparative data between arimoclomol with miglustat and levacetylleucine. It recommended making arimoclomol and levacetylleucine non-preferred with prior authorization, and miglustat (Zavesca) brand was made preferred after evaluation of costs. Both agents are on a list proposed, beginning in January 2026, to be carved out of Coordinated Care Organization payments as medications with an estimated acquisition cost of more than $500,000 per member over a 12-month period.
  • Published economic analyses: one cost-effectiveness analysis in NPC is quoted, a discrete-event simulation of miglustat against symptomatic therapy from the perspective of the Serbian Republic Health Insurance Fund over a time horizon of eighty years, which found miglustat “not cost-effective when compared with symptomatic therapy” with negative values of net monetary benefit regardless of the onset of neurological manifestations. No published economic evaluation of adrabetadex is quoted.

Arimoclomol: wholesale acquisition cost at U.S. introduction, manufacturer filing with the California Department of Health Care Access and Information

Arimoclomol: wholesale acquisition cost on 1 January 2026, manufacturer report to the Texas Department of State Health Services

Levacetylleucine: wholesale acquisition cost at U.S. introduction, manufacturer filing with the California Department of Health Care Access and Information

FieldQuoted record
Manufacturer name“Intrabio Inc.”
National drug code“83853010101”
Drug product description“Aqneursa (levacetylleucine) 1 gram sachet, carton of 28”
Date introduced to market“2024-09-24”
Wholesale acquisition cost at introduction (USD)“13450.0000”

Levacetylleucine: wholesale acquisition cost on 1 January 2025, manufacturer report to the Texas Department of State Health Services

FieldQuoted record
Manufacturer name“IntraBio Inc.”
Drug trade name“Aqneursa”
National drug code“83853010101”
Wholesale acquisition cost on 1 January 2025 (USD)“13450”

Levacetylleucine: Federal Supply Schedule and Big Four prices per carton of 28 packets

Levacetylleucine: New York Medicaid maximum reimbursable amount per packet, list effective 29 September 2026

FieldQuoted record
Description“AQNEURSA 1 GRAM GRANULE PACKET”
National drug code“83853-0101-01”
Maximum reimbursable amount cost“555.7142800”
Basis of maximum reimbursable amount“EA”
Effective date“09/29/2026”
Maximum quantity“112.000”

Arimoclomol: Medicaid utilization and reimbursement, national totals, fourth quarter 2025

Strength and delivery systemQuoted national drug codeQuoted units reimbursedQuoted number of prescriptionsQuoted total amount reimbursed (USD)
124 mg, fee-for-service“72542012401”“1440.000”“16”“1696457.51”
124 mg, managed care“72542012401”“1710.000”“19”“2009670.07”
93 mg, fee-for-service“72542019301”“1170.000”“13”“1033077.71”
93 mg, managed care“72542019301”“1710.000”“19”“1552152.01”
62 mg, fee-for-service“72542016201”“1530.000”“17”“900554.24”
62 mg, managed care“72542016201”“1622.000”“20”“1078098.37”

Arimoclomol: Medicaid utilization and reimbursement, national totals, first quarter 2026

Strength and delivery systemQuoted national drug codeQuoted units reimbursedQuoted number of prescriptionsQuoted total amount reimbursed (USD)
124 mg, fee-for-service“72542012401”“1710.000”“19”“2081853.23”
124 mg, managed care“72542012401”“1170.000”“13”“1436319.97”
93 mg, fee-for-service“72542019301”“1260.000”“14”“1154516.46”
93 mg, managed care“72542019301”“1710.000”“19”“1792307.75”
62 mg, fee-for-service“72542016201”“1713.000”“22”“1203793.11”
62 mg, managed care“72542016201”“1080.000”“12”“670388.98”

Levacetylleucine: Medicaid utilization and reimbursement, national totals by quarter, 2025

Quarter and delivery systemQuoted units reimbursedQuoted number of prescriptionsQuoted total amount reimbursed (USD)Quoted Medicaid amount reimbursed (USD)
First quarter 2025, managed care“2604.000”“33”“1264504.78”“1264504.78”
Second quarter 2025, fee-for-service“3080.000”“36”“1454153.49”“1395177.93”
Second quarter 2025, managed care“4872.000”“61”“2416559.79”“2316942.59”
Third quarter 2025, fee-for-service“6552.000”“79”“3288367.91”“3196467.73”
Third quarter 2025, managed care“6860.000”“84”“3530837.46”“3413044.04”
Fourth quarter 2025, fee-for-service“5852.000”“69”“3020119.38”“2922717.47”
Fourth quarter 2025, managed care“8400.000”“101”“4381592.98”“4193836.02”

Levacetylleucine: Medicaid utilization and reimbursement, national totals, first quarter 2026

Quarter and delivery systemQuoted units reimbursedQuoted number of prescriptionsQuoted total amount reimbursed (USD)Quoted Medicaid amount reimbursed (USD)
First quarter 2026, fee-for-service“7728.000”“93”“4017756.66”“4017744.66”
First quarter 2026, managed care“6076.000”“70”“3160527.34”“2874948.28”

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.